Tango Therapeutics Future Growth
Future criteria checks 2/6
Tango Therapeutics's earnings are forecast to decline at 4.2% per annum while its annual revenue is expected to grow at 30.7% per year. EPS is expected to grow by 0.4% per annum.
Key information
-4.2%
Earnings growth rate
0.4%
EPS growth rate
| Biotechs earnings growth | 20.9% |
| Revenue growth rate | 30.7% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 04 Apr 2024 |
Recent future growth updates
Recent updates
Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%
Mar 19
Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans
Mar 06Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk
Jan 08Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)
Aug 12Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?
May 10Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer
Oct 20Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth
Oct 05Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 13Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M
Aug 10We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn
May 28We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow
Jan 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 34 | -177 | -173 | -171 | 7 |
| 12/31/2025 | 33 | -149 | -148 | -150 | 7 |
| 12/31/2024 | 32 | -131 | -128 | -133 | 7 |
| 12/31/2023 | 37 | -102 | -120 | -118 | N/A |
| 9/30/2023 | 38 | -100 | -121 | -119 | N/A |
| 6/30/2023 | 34 | -107 | -113 | -107 | N/A |
| 3/31/2023 | 25 | -111 | -121 | -114 | N/A |
| 12/31/2022 | 25 | -108 | -117 | -109 | N/A |
| 9/30/2022 | 24 | -101 | -105 | -98 | N/A |
| 6/30/2022 | 24 | -92 | -104 | -100 | N/A |
| 3/31/2022 | 36 | -71 | -79 | -76 | N/A |
| 12/31/2021 | 37 | -58 | -61 | -60 | N/A |
| 9/30/2021 | 40 | -45 | -62 | -61 | N/A |
| 6/30/2021 | 22 | -52 | 71 | 72 | N/A |
| 3/31/2021 | 9 | -56 | 67 | 69 | N/A |
| 12/31/2020 | 8 | -52 | 69 | 70 | N/A |
| 12/31/2019 | 25 | -14 | -27 | -25 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TNGX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TNGX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TNGX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TNGX's revenue (30.7% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: TNGX's revenue (30.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TNGX's Return on Equity is forecast to be high in 3 years time